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Abstract
 
The molecular basis of CD28-dependent costimulation of T cells is poorly understood. Bcl-x
 
 
 
is a member of the Bcl-x family whose expression is restricted to activated T cells and requires
CD28-dependent ligation for full expression. We report that Bcl-x
 
 
 
–deficient (Bcl-x
 
 
 
 
 
/
 
 
 
) T
cells display defective proliferative and cytokine responses to CD28-dependent costimulatory
signals, impaired memory responses to proteolipid protein peptide (PLP), and do not develop
PLP-induced experimental autoimmune encephalomyelitis (EAE). In contrast, enforced ex-
pression of Bcl-x
 
 
 
 largely replaces the requirement for B7-dependent ligation of CD28. These
findings identify the Bcl-x
 
 
 
 cytosolic protein as an essential downstream link in the CD28-
dependent signaling pathway that underlies T cell costimulation.
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Introduction
 
The T cell response to antigen requires costimulatory sig-
nals that promote efficient T cell expansion and cytokine
secretion. Transduction of costimulatory signals by the
CD28 receptor is a pivotal element in the full stimulation
of T cells and prevention of anergy in vitro (1). CD28-
dependent signals are also required for effective in vivo T
cell responses to allografts (2) and for development of ex-
 
perimental autoimmune encephalomyelitis (EAE;
 
*
 
 reference
3). Recent studies have suggested that CD28-dependent
effects on T cell survival and proliferation may represent
biochemically distinct pathways that originate from differ-
ent sites on the CD28 molecule’s cytoplasmic domain. One
pathway, marked by Bcl-xL expression, may contribute to
T cell survival upon growth factor withdrawal in vitro (4)
and may enhance survival of mature thymocytes (5, 6) and
peripheral T cells (7, 8). A second pathway, proposed to
account for the biologic signature of CD28-dependent co-
stimulation-enhanced proliferation and cytokine produc-
tion, has not been well characterized (9, 10).
Bcl-x
 
 
 
, a recently identified isoform of the Bcl-x gene, is
expressed after TCR and CD28 ligation and may contrib-
ute to successful proliferation and IL-2 secretion after stim-
 
ulation by antigen (11). Importantly, the expression of
 
Bcl-x
 
 
 
 is mainly confined to the T cell compartment (11),
while Bcl-xL has a much wider tissue distribution (4).
These findings opened the possibility that Bcl-x
 
 
 
 function
may be more specifically tailored to T cell activation. In
contrast, Bcl-xL, which exerts antiapoptotic activity in a
wide variety of different cell types (4), can enhance the sur-
vival, but not proliferation of activated T cells (8). There-
fore, it was of interest to determine whether Bcl-x
 
 
 
 func-
tion might overlap with Bcl-xL and potentiate cell survival
or exert a distinctive and complementary role in T cell ac-
tivation. To this end, we generated mice that either lack or
 
constitutively express Bcl-x
 
 
 
 in T cells. We find that
Bcl-x
 
 
 
–deficient T cells fail to respond to CD28-depen-
dent costimulatory signals according to cell proliferation
and cytokine expression, while enforced expression of
Bcl-x
 
 
 
 largely replaces the requirement for CD28-depen-
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dent costimulatory signals; manipulation of Bcl-x
 
 
 
 expres-
sion had no significant effect on T cell survival.
 
Materials and Methods
 
Generation of Bcl-x
 
 
 
 Tg Mice.
 
Bcl-x
 
 
 
 Tg mice containing
full-length Bcl-x
 
 
 
 cDNA under control of the Lck
 
Dis
 
 (p56
 
lck
 
)
promoter (12) were generated and backcrossed to C57BL/6 for
eight generations. Enforced expression of Bcl-x
 
 
 
 (in a T cell–spe-
cific manner) in these transgenic mice was confirmed by Western
blot analysis as well as by RT-PCR, using oligos that distinguish
transgenic and endogenous RNA transcripts. C57BL/6 Bcl-x
 
 
 
 Tg
mice were also crossed with Balb/c DO11.10 TCR Tg mice to
generate C57BL/6 
 
  
 
Balb/c Bcl-x
 
 
 
 Tg DO11.10 TCR Tg mice
and Bcl-x
 
 
 
 wild-type (wt) DO11.10 TCR Tg control litter-
mates.
 
Transfection and Screening of Embryonic Stem Cells and Generation
of Bcl-x
 
 
 
 
 
 
 
/
 
 
 
 Mice.
 
TC1 embryonic stem (ES) cells were elec-
troporated with 15 
 
 
 
g of PvuI-linearized Bcl-x
 
 
 
 
 
/
 
 
 
 vector DNA
and selected in media containing G418 and Gancyclovir as de-
scribed previously (14). Bcl-x
 
 
 
 
 
/
 
 
 
 ES cells were identified by
Southern blot analysis using the 5
 
 
 
 knockout probe on HindIII-
digested DNA and confirmed by using the 3
 
 
 
 knockout probe on
BglII-digested DNA. Bcl-x
 
 
 
 
 
/
 
 
 
 ES cells were transiently trans-
fected by electroporation with 30 
 
 
 
g/ml of pMC-CreN, and
clones were isolated and screened by Southern blot analysis for
Cre-
 
loxP
 
–mediated deletion of the neo
 
r
 
 gene. Targeted TC1 ES
cells were used to generated chimeric mice. Bcl-x
 
 
 
 
 
/
 
 
 
 ES cells
were injected into C57BL/6 blastocysts, and chimeric mice capa-
ble of transmitting the Bcl-x
 
 
 
 
 
/
 
 
 
 allele to offspring were ob-
tained from two independent clones. Offspring from these mice
were bred to 129sv to generate Bcl-x
 
 
 
 
 
/
 
 
 
, Bcl-x
 
 
 
 
 
/
 
 
 
, and Bcl-
x
 
 
 
 
 
/
 
 
 
 mice.
 
Flow Cytometry.
 
Single-cell suspensions were prepared from
thymus, spleen, and LNs, where indicated. Erythrocytes were lysed
with ammonium chloride lysis buffer, and cells were washed
in 2% FBS/PBS. Cell surface molecules were detected by staining
10
 
6
 
 viable cells with indicated conjugates for 20 min at 4
 
 
 
C in 2%
FBS/PBS. Cells were stained with FITC or R-phycoerythrin or
Cy-Chrome–conjugated antibodies. Data from 
 
 
 
50,000 size-
gated cells were acquired on a Coulter Epics XL flow cytometer
(Beckman Coulter).
 
Southern Blot Hybridization.
 
Genomic DNA was isolated and
Southern blotting was performed as described previously (13), us-
ing Zetaprobe membranes (Bio-Rad Laboratories) and probes
generated by random hexamer priming (Boehringer Mannheim)
using (
 
 
 
-
 
32
 
P)dCTP (NEN Life Science Products). The 5
 
 
 
 knock-
out probe is a 1-kb NotI-EcoRI genomic fragment, and 3
 
 
 
knockout probe is a 600-bp MscI-XbaI genomic DNA fragment.
 
RT-PCR and Touchdown PCR Analysis.
 
Total RNA was pre-
pared from cultured T cells and mouse thymus using RNA-
zole (Tel-Test, Inc.). RT-PCR and PCR cloning were per-
formed as described previously (4). In brief, total RNA from
mouse thymus was reverse transcribed in a GeneAmp PCR 9600
(Perkin-Elmer) using a GeneAmp RNA-PCR kit (Perkin-
Elmer) at 45
 
 
 
C for 60 min, followed by 95
 
 
 
C for 3 min, and then
placed on ice. For Bcl-x
 
 
 
 detection, primers (e4f: 5
 
 
 
-GGA ATT
CAG TGG AGG TAC ACC CCT CAG ATCT-3
 
 
 
 and e4b: 5
 
 
 
-
CCA CTC CTG GCA CTT GAA CAA GCCT-3
 
 
 
) specific for
the 5
 
 
 
 and 3
 
 
 
 ends of exon 4 were used (see Fig. 1 A). To detect
Bcl-xL, primers to exon 2 (3e: 5
 
 
 
-TCG CTC GCC CAC ATC
CCA GCT TCA CAT AAC CCC-3
 
 
 
) and exon 3 (15e: 5
 
 
 
-
CCA CCA ACA AGA CAG GCT-3
 
 
 
) were used (see Fig. 1 A).
 
Each three-step thermal cycle for routine PCR analysis consisted
of 30 s at 95
 
 
 
C, 30 s at 60
 
 
 
C, and 60 s at 72
 
 
 
C. Additional PCR
reactions were performed for 35–40 cycles using Advantage
cDNA Polymerase Mix (CLONTECH). PCR products were vi-
sualized by agarose gel electrophoresis and ethidium bromide
staining, and were positively identified by size markers. A nega-
tive control containing all reagents except cDNA was included in
each PCR analysis.
 
Western Blot Analysis.
 
For immunoblot detection of Bcl-x
 
 
 
and Bcl-xL protein, 100 
 
 
 
g of primary T cell PNS (per lane)
were resolved on SDS-polyacrylamide gels containing 10% acryl-
amide and 0.27% N,N
 
 
 
-methylene bis-acrylamide under nonre-
ducing conditions. To obtain better separation of Bcl-x
 
 
 
 and
Bcl-xL proteins, a full-length gel apparatus of 20 
 
  
 
20 cm was
used. After electrophoresis, proteins were transferred to PVDF
membranes (Millipore). Membranes were blocked, washed, and
probed with an affinity-purified rabbit anti–Bcl-x antibody
(R&D Systems) at a final concentration of 0.3 
 
 
 
g/ml. To con-
firm the identity of the (top) Bcl-x
 
 
 
 band, membranes were
stripped and reprobed with an affinity-purified rabbit antibody
(1.0 
 
 
 
g/ml) specific to the unique COOH terminus of Bcl-x
 
 
 
.
HRP-conjugated secondary antibodies and chemiluminescence
detection reagents were from Amersham Pharmacia Biotech.
 
IL-2 Production and T Cell Proliferation.
 
CD4
 
 
 
 T cells were
isolated from LNs of Bcl-x
 
 
 
 
 
/
 
 
 
, Bcl-x
 
 
 
 
 
/
 
 
 
, or Bcl-x  Tg mice
by negative section. In brief, LN cells were incubated with rat
anti–mouse B220, Mac-1, Gr-1, CD8, and NK1.1 antibodies
(BD PharMingen) for 30 min, washed, and incubated with mag-
netic beads coated with sheep anti–rat antibody (Dynal) for 45
min. Finally, antibody-coated cells were removed by magnetic
separation and the isolated T lymphocytes were washed again.
LN T cells (5   105 cells per well) were cultured in triplicates in
round-bottomed 96-well plates (Costar) in 200  l of freshly pre-
pared Iscove’s DMEM (10% FCS, 50  M 2-mercaptoethanol).
T cells were activated by culturing in the presence of plate-
bound anti-CD3 (145.2C11 clone) and anti-CD28 antibodies
(BD PharMingen) at final concentrations of 0.2 and 1.0  g/ml,
respectively. Alternatively, soluble anti-CD3 (1  g/ml) and IL-2
(BD PharMingen) were used at the indicated concentrations. T
cells were cultured for 48 h, and 1  Ci 3[H]thymidine was added
to the wells for the last 18 h of culture. T cell culture superna-
tants were assayed for IL-2 in triplicates at indicated time points
by ELISA. Where indicated, supernatants were harvested after
24, 48, and 72 h of culture. IL-2 levels were determined by
sandwich ELISA, according to the manufacturer’s instructions
(BD PharMingen).
EAE Induction Using Proteolipid Protein Peptide. EAE was in-
duced in mice by immunization with a 12mer peptide represent-
ing amino acids 172–183 (PVYIYFNTWTTC) of proteolipid
protein peptide (PLP)172–183. Per mouse, 150  g of PLP pep-
tide and 300  g of killed Mycobacterium tuberculosis in CFA were
injected (subcutaneously), by means of three injections over the
flanks. In addition, 400 ng of pertussis toxin was injected, intra-
peritoneally on days 0 and 2. Disease was scored as follows: score
0, normal mouse with no sign of disease; score 1, limp tail; score
2, limp tail and partial hind limb weakness; score 3, partial hind
limb paralysis; score 4, complete hind limb paralysis; and score 5,
moribund state per death by EAE.
Apoptosis Assays. 24- or 96-well plates containing plate-
bound anti-CD3 antibody (0.1–0.2  g/ml, clone 145.2C11; BD
PharMingen) were washed three times with PBS before addition
of cells. Cells (either 5   106 or 5   105 cells per well) were
washed twice with PBS at the indicated times, and resuspended89 Ye et al.
in 1  Annexin V binding buffer. Cells in the early stages of
apoptosis measured positive for fluorescein-Annexin V (Annexin
V-FITC; BD PharMingen) as determined in an Epics XL FAC-
Scan™ using standard settings in semilogarithmic mode, and
these cells contained higher forward scattering levels (for gating)
than dead cells in the samples. Fully activated T cells from Bcl-
x  /  mice exhibited a 10–20% increase in apoptosis versus con-
trol (wt) cells while the levels of apoptosis in nonactivated Bcl-x 
Tg  T cells were only 10–30% lower compared with nonacti-
vated control T cells. In certain experiments, cells were stained
with FITC-conjugated anti-CD3 antibody or propidium iodide
(PI) (BD PharMingen) before measurement of cell survival.
PI Fluorescence. The percentage of cells in G0/G1, S, and G2/M
phases was determined by cytofluorometric analysis after PI
staining.
For PI staining,  106 cells were suspended in 100  l PBS and
1 ml of ice-cold 80% ethanol was added drop-wise, while vortex-
ing. Samples were then incubated for 1 h on ice. Cells were then
washed gently twice with PBS, and resuspended in 250  l of PBS
containing 12.5  g of RNase. Cells were incubated at 37 C for
30 min before staining cellular DNA with 250  l of a PI solution
(50  g/ml) in PBS for 1 h at 37 C. Cells were then immediately
place on ice and analyzed using FACScan™. The 1n chromo-
some-containing lymphocyte peak (main peak) was set to identi-
cal values on the semilogarithmic scale at the beginning of each
analysis. Cell yields from cultures of Bcl-x  wt,  / , or Bcl-x 
Tg T cells were not significantly different at the time of analysis
(36 h after stimulation).
Adoptive Transfer and CFSE Labeling of Donor Cells. Periph-
eral and mesenteric LN lymphocytes from Bcl-x  wt and  / 
mice were isolated and washed in 2% FBS/PBS. To monitor the
proliferation of these donor cells in recipient (syngenic Bcl-x  wt)
mice, CFSE (Molecular Probes) labeling was performed by incu-
bating 107 cells per milliliter in PBS/0.1% BSA with CFSE (final
concentration 10  M) for 10 min at 37 C. Labeled cells were
washed twice with PBS/0.1% BSA before they were resuspended
in sterile PBS for tail vein injection. Approximately 5   106 of
CFSE-labeled cells were injected, intravenously, per mouse.
Results
Generation of Bcl-x –deficient Mice. We selectively dis-
rupted this isoform within the Bcl-x locus to generate Bcl-
x –deficient mice. Analysis of Bcl-x  and Bcl-x genomic
structure (14) has indicated that mature Bcl-x  RNA tran-
scripts are comprised of coding exons 1, 2, and 4 (Fig. 1 A)
joined with alternatively-spliced combinations of exons
5–8 that comprise several distinct noncoding 3 -UTR (14).
We generated Bcl-x –deficient mice (Materials and Meth-
Figure 1. Generation of Bcl-x  / 
mice. (A) Schematic representation
of the coding and noncoding exons
of Bcl-x  and Bcl-xL. Exon 1 en-
codes the distal portion of the 5  un-
translated region (UTR), and exon 2
encodes the remainder of the 5 
UTR and the common NH2 termi-
nus of Bcl-xL and Bcl-x  proteins.
Exon 3 encodes the COOH termi-
nus of Bcl-xL, as well as the 3  UTR
of Bcl-xL. Exon 4 encodes the
unique COOH terminus of Bcl-x 
protein and alternative splicing of
exons 5–8 regulates expression of
the Bcl-x  3   UTR. (B) Strategy
used to generate Bcl-x –deficient
mice is shown based on targeted dis-
ruption of exon 4, the coding region
for the unique COOH terminus of
Bcl-x , as described in Materials and
Methods. The genomic structure
surrounding exon 4 and the struc-
ture of the targeting vector and mu-
tant gene is shown. (C, left) South-
ern blot of murine Bcl-x   ( / ,
 / , and  / ) (see Materials and Methods); (right) RT-PCR analysis of RNA (1  g per sample) derived from Con A-activated LN T cells of Bcl-x 
wt,  / , and  /  mice. PCR primers used to detect Bcl-x  and Bcl-xL are indicated in Fig. 1 A and detailed in Materials and Methods. (D) Expression
of Bcl-x  and Bcl-xL protein after CD3/CD28 ligation. (left) Time-course analysis of Bcl-x  and Bcl-xL protein in T cells from wt mice after CD3 and
CD28 ligation. T cells isolated from wt and  /  mice were incubated for the indicated intervals in the presence of plate-bound anti-CD3 antibody (0.2
 g/ml) or anti-CD3 (0.2  g/ml) and anti-CD28 antibody (1.0  g/ml); 100  g of after nuclear supernatant (PNS) loaded per lane. (right) Bcl-x  and
Bcl-xL protein levels in T cells derived from wt and  /  mice activated as described above for 48 h. The upper band (corresponding to Bcl-x ) was
confirmed by reprobing the same blots with an antibody specific to the unique COOH terminus of Bcl-x  (see Materials and Methods). The immuno-
blots shown are representative of one of three independent experiments and were overexposed to provide sensitive detection of trace amounts of Bcl-x ,
while increased levels of Bcl-xL in CD3 and CD3/CD28 cells are noted. Increasing the concentration of plate-bound anti-CD3 alone (up to 5  g/ml)
was not sufficient to induce significant levels of Bcl-x  in the absence of CD28 ligation. The blots for actin served as a control for protein loading. (E)
Expression of Bcl-xL in wt and Bcl-x  /  LN after anti-CD3 and anti-CD28 ligation. LN from wt and Bcl-x  /  mice were stimulated with plate-
bound anti-CD3 or anti-CD3 plus anti-CD28 for 48 h before Bcl-xL expression was confirmed by Western blot analysis with anti–Bcl-x antibody. Ex-
pression of Bcl-xL in both strains is similar, indicating that loss of the Bcl-x  gene does not affect expression of Bcl-xL. Actin was used as a loading con-
trol, after membranes were stripped and reprobed with anti-actin antibody.90 Bcl-x  and T Cell Costimulation
ods) using a Cre/LoxP-mediated gene targeting vector to
delete exon 4 in ES cells as outlined in Fig. 1 B. Southern
blot analysis of tail cut DNA from ES cell–injected mice
showed that exon 4 had been successfully disrupted (Fig. 1
C, left panel). Additional RT-PCR analysis with primers
specific for exon 4 (for Bcl-x ) or exons 2 and 3 (for Bcl-
xL) confirmed that Bcl-x  mRNA was no longer ex-
pressed while Bcl-xL mRNA expression was unchanged in
the same activated T cells in three independent experi-
ments (Fig. 1 C). To document the effect of this mutation
on Bcl-x  and Bcl-xL protein expression, Western blotting
of Bcl-x  and Bcl-xL after coligation of CD3 and CD28
was performed. These experiments confirmed other studies
(14) that CD28 coligation is essential for full and early ex-
pression of Bcl-x  in activated T cells (Fig. 1 D, left panel
and legend). They also showed that CD3/CD28 coligation
failed to induce detectable Bcl-x  protein in Bcl-x  /  T
cells after overexposure of Western blots (Fig. 1 D, right
panel). At the same time, expression of Bcl-xL protein after
CD3 or CD3/CD28 ligation was indistinguishable in Bcl-
x  /  and Bcl-x  wt T cells according to normally ex-
posed Western blots (Fig. 1 E).
Proliferative Responses of Bcl-x –deficient and Bcl-x  Tg T
Cells In Vitro. We measured the effects of CD3 and
CD28 coligation on the proliferative and IL-2 responses of
Bcl-x  /  T cells (15, 16). As expected, CD3/CD28 coli-
gation of wt T cells resulted in a 4–6-fold increase in
3[H]thymidine incorporation and IL-2 production com-
pared with anti-CD3 alone; however, CD28 coligation
failed to augment the response of T cells from Bcl-x  / 
mice (Fig. 2, A and B), suggesting that the Bcl-x  mutation
nullifies CD28-dependent costimulation.
Then, we asked whether enforced expression of Bcl-x 
in T cells might replace the need for CD28-dependent co-
stimulation. Expression of a Bcl-x  transgene under the
control of the Lck distal promoter resulted in constitutive
overexpression of Bcl-x  in peripheral T cells independent
Figure 2. Proliferation profile and cytokine production of T cells from
Bcl-x  wt and  /  mice after CD3 and CD28 ligation. (A) Proliferation
of activated T cells from wt and  /  mice. T cells were isolated from wt
and  /  mice and cultured for 48 h in the presence of plate-bound anti-
CD3 and/or anti-CD28 antibodies. Cells were then pulsed with 3[H]thy-
midine and cultured for an additional 18–20 h before harvesting. Data
( SEM) represents the mean thymidine uptake of triplicate cultures as
described in Materials and Methods. (B) Time-course of IL-2 production
from activated T cells. Supernatants from T cells activated as described in
(A) were harvested at the indicated times and analyzed for IL-2 by ELISA.
Values are the average of triplicate determinations ( SE) from one of
three representative and independent experiments as described in Materi-
als and Methods.
Figure 3. Expression and proliferation profiles of Bcl-x  in cells de-
rived from Tg mice. (A) Expression of Bcl-x  and Bcl-xL in different
murine tissues from Tg mice (see Materials and Methods). Immunoblot
analysis was performed as described in Materials and Methods and is rep-
resentative of data in one of two independent experiments; the level of
actin serves as a control for protein loading. (B) Proliferation of activated
T cells from wt and Tg mice. T cells were isolated from Tg or wt mice
and cultured for 48 h in the presence of plate-bound anti-CD3 and/or
anti-CD28 antibodies. Cells were then pulsed with 3[H]thymidine and
cultured for an additional 18 h before harvesting. In the absence of anti-
body-dependent activation, survival of T cells from Bcl-x  Tg and wt
mice was not significantly different after 24–72 h in culture. (C) Time-
course of IL-2 production from activated T cells. Supernatants from T
cells activated as described above were harvested at the indicated times
and analyzed for IL-2 by ELISA. All values are the average of triplicate
determinations ( SEM) from one of four representative and independent
experiments. (D) Proliferative response of T cells from Bcl-x   and
DO11.10 TCR Tg to OVA peptide (323–339). Purified Bcl-x  trans-
genic and wt T cells (4   104) from DO11.10  littermates (B6.129  
Balb/c genotype) were incubated with irradiated (5   105) splenocytes
from either Balb/c mice or from B7.1 / B7.2 / Balb/c mice for 48 h
before addition of 1  Ci 3[H]thymidine to each well. Proliferation (cpm)
of triplicate cultures was measured after 16 h.91 Ye et al.
of overt activation (Fig. 3 A). Enforced Bcl-x  expression
did not enhance survival of unstimulated T cells, in contrast
to the reported effects of Bcl-xL (Fig. 3 B, legend). How-
ever, proliferative and IL-2 responses of T cells from Bcl-
x  Tg  mice after CD3 ligation were 3–4-fold greater than
T cells from nontransgenic littermates and were not signifi-
cantly increased by CD28 coligation (Fig. 3, B and C).
Moreover, enforced expression of Bcl-x  restored the re-
sponse of CD4 DO11.10  T cells to OVA peptide pre-
sented by B7.1/B7.2 /  APC to levels provoked by B7.1/
B7.2  APC (Fig. 3 D).
Effects of Bcl-x  Deficiency or Forced Expression on Cell Cy-
cling. CD28 costimulation induces cell cycle progression
through IL-2–dependent and IL-2–independent mecha-
nisms (17–19). Although earlier studies of T cell lines that
contained Bcl-x  antisense constructs indicated a critical
role in successful T cell activation, it was not possible to
distinguish between a primary effect on cellular prolifera-
tion versus antigen-induced apoptosis (11) since the ef-
fects of Bcl-x  expression could not be evaluated in non-
transformed T cells. We find that the proliferative
response of Bcl-x  /  T cells to CD3/CD28 coligation
was reduced by  80% according to 3[H]thymidine incor-
poration and IL-2 expression (e.g., Fig. 2), while levels of
apoptosis changed  15%. Levels of apoptosis and cell
death of nonactivated wt. Bcl-x  Tg or Bcl-x  /  T cells
were indistinguishable over a 96-h incubation period
(not shown).
The proliferative response of Bcl-x  Tg,  / , and wt T
cells after TCR ligation was analyzed for alterations in
progress through the cell cycle. Coligation of CD3/CD28
that resulted in a doubling of progression of wt T cells into
G2/M did not enhance progression of Bcl-x  /  T cells
(Fig. 4 A). This observation was complemented by the
finding that enforced Bcl-x  expression largely replaced the
need for CD28 ligation for efficient entry into G2/M (Fig.
4 A). A role for Bcl-x  in the IL-2–independent compo-
nent of CD28-dependent regulation of T cell proliferation
was underlined by the inability of IL-2 to fully restore the
Bcl-x  /  T cell response to CD3 or CD3/CD28 coliga-
tion (Fig. 4, C and D). Finally, we asked whether the re-
duced ability of Bcl-x  /  T cells to proliferate after anti-
body-dependent receptor ligation in vitro was also apparent
in vivo. Analysis of CFSE-labeled Bcl-x  /  T cells in
mice stimulated with the superantigen staphylococcal en-
terotoxin A (SEA; references 20 and 21) revealed that SEA-
dependent replication was reduced by  60% (Fig. 4 B).
Overexpression of Bcl-x  Does Not Protect from Apoptosis or
Activation-induced Cell Death. Bcl-xL has been character-
ized as an essential molecule in the regulation of cell sur-
vival and death (4). It was shown that overexpression of
Bcl-xL could restore cell survival in CD28-deficient T
cells, which normally fail to upregulate this molecule (8).
Similarly, when Bcl-x  was first described, this new iso-
form of Bcl-x appeared to modulate the sensitivity of
CTLL-2 cells to apoptosis after TCR ligation (11). How-
Figure 4. Cell cycle analysis of T
cells after CD3 and CD28 ligation.
(A) In vitro T cells from Bcl-x  wt
and  /  (left) and Bcl-x  wt and
transgenic mice (right) were cul-
tured for 36 h in the presence of
plate-bound anti-CD3 and/or anti-
CD28 antibodies in 24-well dishes
before harvesting. The percentage of
T cells from these mice in G0/G1,
and G2/M phases was determined by
cytofluorometric analysis after PI
staining as described in Materials and
Methods. Results from one repre-
sentative animal in each group are
shown (from one of three indepen-
dent experiments). Levels of an-
nexin-positive cells were not signifi-
cantly different in these groups and
were  15%. (B) In vivo prolifera-
tion of T cells from Bcl-x  wt and
 /  mice after superantigen ad-
ministration. LN and splenic T cells
from donor Bcl-x  wt and  / 
mice were labeled with a fluorescent
chloromethyl derivative, CFSE. La-
beled cells were then transferred in-
travenously into syngenic, recipient
Bcl-x  wt mice as described in Ma-
terials and Methods. The following
day, SEA toxin was injected intraperitoneally, and mice in each group were killed at 3 and 5 d after superantigen exposure. Labeled T cells were analyzed
by flow cytometry as described in Materials and Methods. Results representative of one of two independent experiments are shown. (C and D) Defini-
tion of the contribution of altered IL-2 production to the altered activation pattern of T cells from Bcl-x  /  mice. The response of T cells from Bcl-
x  /  or wt mice to the indicated antibody-dependent ligation in the presence or absence of exogenous IL-2 is shown (see the legend to Fig. 2 and Ma-
terials and Methods).92 Bcl-x  and T Cell Costimulation
ever, levels of apoptosis were found to differ only slightly
between Bcl-x –deficient and wt T cells after TCR stimu-
lation (unpublished data). To further investigate the possi-
ble role of Bcl-x  in the regulation of cell survival and
death, Bcl-x –deficient T lymphocytes were compared
with Bcl-x  Tg cells in their response to cytotoxic agents.
We found no difference in survival between the two cell
types after either irradiation (1,000 rad), treatment with
dexamethasone (5  M) or culture in the absence of stimu-
lation for 96 h (Fig. 5 A). A comparison of the response of
T cells from Bcl-x  Tg/ DO11.10 TCR Tg mice with
cells from Bcl-x  wt/ DO11.10 TCR Tg littermates after
successive stimulation with OVA 323–339 peptide fol-
lowed by TCR religation with anti-CD3 antibody indi-
cated that overexpression of Bcl-x  did not protect cells
from activation-induced cell death (AICD); both groups of
T cells displayed increased cell death and dramatic reduc-
tion of the proliferative response after TCR religation (Fig.
5 B). Together, these results suggest that the proliferative
advantage conferred to T cells by the Bcl-x  transgene is
not mediated through enhanced survival, and that Bcl-x 
does not seem to play an obvious inhibitory role in the
process of apoptosis.
Effects of Bcl-x  Deficiency on the Development of Autoim-
munity. CD28-dependent costimulatory signaling is es-
sential for development of several T cell–mediated au-
toimmune diseases (3, 22, 23) including experimental
autoimmune encephalomyelitis (EAE), which depends on
efficient expansion of T cells that recognize peptides de-
rived from myelin proteins (for a review, see reference
24). In view of the defective CD28-dependent costimula-
tory response of Bcl-x  /  T cells noted above, we de-
fined EAE susceptibility of Bcl-x  /  mice after immuni-
zation with PLP172–183. Bcl-x  /  mice failed to
develop significant EAE compared with substantial disease
displayed by Bcl-x  /  or  /  littermates (Fig. 6 A) and
displayed defective development of T cell memory to
PLP172–183. T cells from PLP-immunized Bcl-x  / 
mice exhibited a substantial (50–100-fold) reduction in
secondary response as judged by PLP-specific proliferation
and IL-2 production after in vitro restimulation by
PLP172–183 peptide (Fig. 6 B).
Although development of thymocytes and T cells from
Bcl-x  /  and Bcl-x  Tg mice was not obviously dysregu-
lated according to FACS® analysis (Table I), levels of mem-
ory T cells, as judged by expression of CD62L and CD44,
were decreased by  50% in Bcl-x  /  mice and increased
by this amount in Bcl-x  Tg mice (Fig. 6 C). These find-
ings suggest a direct correlation between Bcl-x  expression
and successful generation of memory T cells secondary to
experimental (Fig. 6, A and B) or environmental (Fig. 6 C)
antigenic stimuli.
Discussion
An efficient T cell response to antigen requires costimu-
latory signals provided by the CD28 receptor that promote
cell expansion and cytokine secretion. Although the im-
portance of CD28 ligation to complete T cell activation is
well documented (25), its molecular basis remains poorly
understood. Since expression of the Bcl-x  isoform is
tightly coupled to CD28/CD3 coligation, we investigated
its potential role in expression of the costimulatory pheno-
type using mice containing T cells that specifically lack or
overexpress this member of the Bcl-x family.
LoxP-dependent excision of exon 4 of the Bcl-x gene
eliminated Bcl-x  expression without a detectable effect on
expression of Bcl-xL at the RNA or protein level (Fig. 1).
This genetic lesion was associated with defective T cell
memory in vivo; Bcl-x  /  mice displayed reduced num-
bers of CD45RB  CD44hi T cells, reduced secondary re-
sponses after restimulation with PLP172–183 peptide, and
failed to develop PLP-induced EAE. Analysis of the re-
sponse of Bcl-x  /  T cells in vitro mapped this phenotype
to a defect in CD28-dependent costimulation, since CD3-
dependent activation was unimpaired while CD28 coliga-
tion failed to enhance 3[H]thymidine incorporation, IL-2
production, and entry into G2/S. These findings were
Figure 5. Effect of Bcl-x  on
apoptosis and AICD. (A) Effect
of Bcl-x  expression on survival
to cytotoxic treatments. Spleno-
cytes from Bcl-x  /  and Bcl-x 
Tg mice (106 cells per well on a
24-well plate) were cultured in
complete medium either after
irradiation (1,000 rad), addition
of DEX (5  M), or no addition.
Cells were collected at the time
points shown and stained for
CD4 expression and PI incor-
poration. Percentages of dead
CD4  T cells were determined
by flow cytometry (percentage of PI-positive cells in the CD4  population). (B) Effect of Bcl-x  overexpression on AICD. Splenocytes from Bcl-x  Tg
and wt mice (3   105) were stimulated with OVA 323–339 (0.01, 0.1, and 1  M) or cultured without peptide. After 48 h, the cells were transferred
onto fresh microtiter plates which were either uncoated or coated with anti-CD3 (1  g/ml at 4 C for 16 h). 3[H]thymidine was added at the same time
and proliferation was measured 18 h later (left). Alternatively, no 3[H]thymidine was added, and the cells were collected for flow cytometry (stained for
CD4 expression and PI incorporation) 20 h after transfer. The percentages of PI-positive cells within the CD4  population are shown (right). Results are
representative of two similar experiments.93 Ye et al.
complemented by studies showing that enforced expression
of Bcl-x  largely replaced the need for CD28-dependent
costimulation and the response of Bcl-x  Tg T cells to
CD3 ligation was similar to the response of nonTg T cells
to CD3/CD28 coligation.
Ligation of CD28 enhances T cell proliferation through
increased expression of IL-2 as well as IL-2–independent
acceleration of entry into cell cycle (17, 25, 26). Bcl-x 
appears to contribute to both elements of costimulation;
although Bcl-x  /  T cells display reduced IL-2 produc-
tion, reduced proliferation is only partially remedied by
exogenous IL-2 and IL-2–independent entry of Bcl-x –
deficient T cells into G2 is impaired (Fig. 4). Since expres-
sion of other Bcl-x isoforms including Bcl-xL is unaltered
in these cells (Fig. 1), these experiments underline the es-
sential intracellular role of Bcl-x  in expression of CD28-
dependent costimulation.
Initial studies of Bcl-x  showed that this Bcl-x isoform is
expressed in T cells that successfully proliferate after en-
gagement of the TCR by peptide antigen, whereas expres-
sion of Bcl-x antisense constructs in T cell lines reduced
proliferation and increased apoptosis (11). However, analy-
sis of the effects of dysregulated Bcl-x  gene expression in
transformed cells did not delineate the potential role of this
cytosolic protein in T cell proliferation and CD28-depen-
dent costimulation. The finding that CD28-dependent co-
stimulation depends on expression of the cytosolic Bcl-x 
protein supports an emerging view that CD28-dependent
enhancement of T cell survival and T cell proliferation to
antigen may reflect separate signaling pathways originating
from distinct regions of the CD28 cytoplasmic domain (9,
10). Other studies have indicated that Bcl-xL expression
Figure 6. Induction of EAE in Bcl-x  wt and  /  mice. (A) Mean
clinical scores. Animals were immunized with the a PLP, PLP172–183;
wt, n   9, and  / , n   9. Scoring of disease development in (C57BL/6  
129)F2 littermates that carried the Bcl-x  /  ( / ) or wt ( /  and  / )
genotype is shown based on the mean scores of two independent experi-
ments ( SEM) as described in Materials and Methods. (B, left) Prolifera-
tive responses of PLP peptide-specific T cells from wt and  /  mice. T
cells were stimulated in vitro with PLP peptide in the presence of irradi-
ated APCs. Data ( SE) represents the mean thymidine uptake of triplicate
cultures. (Right) PLP peptide-specific IL-2 production (measured by
ELISA) from draining LN cells of Bcl-x  wt and  /  mice. T cells were
activated in vitro with PLP peptide in the presence of irradiated APCs.
Values are the average of triplicate determinations ( SEM). (C) FACS®
analysis of CD4 and CD8 T cells from Bcl-x  / , Bcl-x  Tg, and Bcl-x 
wt mice according to expression of CD44hi, CD62L, and CD45RB. LN
cells from Bcl-x  Tg,  / , and control (littermate) mice were isolated
and analyzed by flow cytometry (16) for the indicated cell surface/activa-
tion markers expressed by LN cells (3.5   107 cells per animal). Data
shown are the average values from four mice (for each genotype) that were
6 mo of age (  1 wk) and expressed as a percentage of wt values.
Table I. FACS® Analysis of Lymphoid Cells from Bcl-x  /  and 
Bcl-x  Tg Mice
Thymus Bcl-x  wt Bcl-x  /  Bcl-x  Tg
%
DN 2.7 1.9 2.4
DP 82.1 86.5 85.3
CD4 SP 11.5 8.2 9.7
CD8 SP 3.8 3.4 2.6
TCR- + 18 17.5 19.4
CD3+ 14.4 12.7 19.7
HAS+ 90.3 92.4 93.2
CD69+ 15.6 14.1 13.4
Spleen (%)
CD4 T cell 60.3 62.8 62.1
CD8 T cell  30.7 27.2 31.2
DN T cell  9 9.5 6.7
CD19/B220 28.2 29.6 27.7
B220/CD8 6.4 6.4 7.8
NK1.1 1.2 1.1 1.1
TCR- + 56.2 58.5 61.2
TCR- + 0.6 0.7 0.4
LN (%)
CD4 T cell  64.9 60.9 64
CD8 T cell  32.7 36.3 33.4
DN T cell  2.5 2.8 2.3
CD19/B220 8.8 10.1 9.7
B220/CD8 1.9 1.5 1.4
NK1.1 1.5 1.2 0.8
TCR-  87.9 87 91.2
TCR-  0.8 0.6 0.5
Data shown are representative of one of three independent experiments
with groups of three to four mice (8–12 wk of age).94 Bcl-x  and T Cell Costimulation
marks a costimulatory signaling pathway that contributes to
T cell survival (4, 7) but not proliferation or cytokine ex-
pression after antigen stimulation (8–10). Our studies sug-
gest that Bcl-x  expression is essential for enhanced entry
into cell cycle and IL-2 production after TCR ligation, but
not for protection from AICD or irradiation or dexametha-
sone-induced apoptosis. Furthermore, overexpression of
Bcl-x  did not enhance cell survival in the absence of stim-
uli or after TCR ligation. These findings support a division
of labor among the Bcl-x isoforms that relies on Bcl-x  en-
hancement of T cell proliferation and Bcl-L to potentiate
cell survival after CD28 ligation.
Unlike Bcl-xL, which is tethered to the outer surface of
mitochondrial membranes, the Bcl-x  protein locates in
the cytosol, lacks a hydrophobic tail, and may be phos-
phorylated at serine/threonine (14). A two-hybrid screen
using the unique COOH terminus of Bcl-x  has suggested
that the Jun-binding protein QM (27, 28) specifically in-
teracts with Bcl-x , and not Bcl-xL (unpublished data),
opening the possibility that CD28-dependent induction of
Bcl-x  may facilitate DNA binding of AP-1 or Jun/Jun
dimers. Alternatively, Bcl-x  may interact with caspases
and/or caspase-activating molecules in a similar fashion to
Bcl-xL (29). According to the latter view, Bcl-x  might
specifically block negatively acting caspases while sparing
stimulatory caspases (30, 31). Insufficient Bcl-x  induction
after incomplete T cell activation would thus allow nega-
tively acting caspases to dampen T cell activation. Al-
though further experiments are required to precisely de-
fine the mechanism of Bcl-x  dependent enhancement
of the T cell response, definition of the complementary
roles of Bcl-x  and Bcl-xL in CD28-dependent costimula-
tion represents an important step toward understanding
this activation process.
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